Market Research Logo

Cell Line Development Services Market, 2017-2027

Cell Line Development Services Market, 2017-2027

The growing pipeline of biological drugs has resulted in a continuous increase in the demand for different types of cell lines. More than 650 biologics have been approved till date, and over 1,500 are under clinical development. Additionally, the loss of patent exclusivity of several biologics in the coming years is likely to be followed by the entry of numerous biosimilars as many companies compete to grab a share of already established drug markets. The importance of cell lines in other areas, such as drug screening, gene functional studies, cell-based assay development, diagnostics and tissue engineering, has resulted in further increase in the demand for different types of cell lines. The rapid progression of biological drug candidates through various phases of development, coupled with the growing demand of cell lines for other applications, presents significant opportunities to cell line development service providers.

The market already has a wide array of well-established players, mid-sized companies and start-ups. Several industry players are contributing to the production of GMP and non-GMP grade cell lines that are obtained from mammalian, microbial, insect-derived, avian, marine, reptilian and other sources. Stakeholders have entered into multiple partnerships / collaborations in order to improve and scale-up production processes, and expand their capabilities. Considering the heightened activity in this domain, we believe the market is likely to evolve at a steady pace in the mid to long term, driven primarily by the increasing demand for cell lines, and advances in technology platforms and production methodologies.

SCOPE OF THE REPORT
The ‘Cell Line Development Services Market, 2017 - 2027’ report provides an extensive study of the rapidly growing market of cell lines. Cells obtained from mammalian and microbial sources are widely used for the development and manufacturing of biotherapeutic products, such as recombinant proteins, antibodies and vaccines. Mammalian cell lines, owing to their inherent high productivity and ability to produce complex biopharmaceuticals, are relatively more preferred. At the same time, microbial cell lines are also widely used due to their less complex nature, low cost and high versatility.

As mentioned earlier, in addition to the large number of biologics that are already available in market, many are under various stages of development. In fact, close to 50% of product candidates in the current development pipeline are in the preclinical stage. Moreover, a number of important biologics, such as Aransep®, Avastin®, Herceptin®, HUMIRA®, Neulasta® and REMICADE®, are approaching patent expiration, and several companies are already engaged in the development of biosimilars and biobetters. As of May 2017, five biosimilars in the US and 28 in Europe have been approved. In addition to the US and EU, several companies based in Asia are also focused on the development of biosimilars. These developments have led to an upward surge in the demand for highly-productive and stable cell lines. High yielding cell lines, capable of producing top quality biopharmaceuticals, help in significantly reducing development and manufacturing costs. Hence, several companies have designed and developed innovative systems / technologies / proprietary manufacturing processes in order to optimize manufacturing costs and production timelines of the overall cell line development process. In addition to development-related services, several cell line manufacturers provide other services related to cell lines as a part of their respective services portfolios; examples of these services include cell line characterization, cell banking, cell bank characterization, process development and commercialization of reagents / equipment. It is also important to highlight that some of these companies offer cGMP production of biologics and fill / finish of end products as well.

This study presents an in-depth analysis of companies that are actively involved in providing cell line development services. In addition to other elements, the study features:
 A discussion on the database of cell line development service providers along with information on the location of their manufacturing facilities, distribution of cell lines based on the source from which they are obtained (mammalian, microbial, insect-derived, avian, marine and reptilian), type of cell lines (recombinant, hybridoma and primary cell lines), technology used for the production of cell lines, purpose of production (R&D, diagnostics, biomanufacturing and tissue engineering), and other associated services (cell line characterization, cell banking, cell bank characterization, process development, cGMP manufacturing of biologics, fill / finish of end products and commercialization of reagents / equipment).
 A detailed analysis of the database presented as three schematic representations; a world map depicting the most active geographies in terms of the presence of cell line development facilities, a heat map representing the distribution of database companies on the basis of their location (continent-wise distribution), year of establishment and cell line development capabilities, and a logo landscape signifying the distribution of companies based on the number of employees and the source from which cell lines are obtained.
 Elaborate profiles of key industry players that have proprietary technologies for the development of cell lines and offer cell line characterization, cell banking and cGMP production of biologics as part of their services portfolios; each profile features an overview of the company, its financial performance, information on cell line development services and proprietary technology, manufacturing facilities, expansions and collaborations, and a comprehensive future outlook.
 Profiles of non-industry players (cell line repositories) that play an active role in the development of cell lines and offer affiliated services; each profile features an overview of the repository and a brief description about its cell line development services.
 Potential future growth opportunities in the cell line development market, segmented by regions, source and grade of cell lines. For the purposes of this analysis, we took into consideration several parameters, such as the number of companies involved, price of cell lines depending upon whether they are characterized or uncharacterized, source of cell lines, and average annual cell line development projects undertaken by companies.

We have provided informed estimates of the size of the market in the short to mid-term and long term for the period 2017-2027. To account for the uncertainties associated with the development of cell lines and to add robustness to our model, we have provided three forecast scenarios portraying conservative, base and optimistic tracks of the market’s evolution. The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. For the purpose of the study, we invited over 100 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities and challenges that must be considered for a more inclusive growth. The insights presented in this study were also influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with Fan Chen (Vice President Bioprocessing, LakePharma), Michael Pointek (Managing Director, Artes Biotechnology), Nienke Smits (Business Development, Modiquest) and Oscar Hoogteijling (Business Development Manager, Bioceros).
EXAMPLE HIGHLIGHTS
1. Over 180 companies are actively providing cell line development services to several biopharmaceutical companies. Majority of these companies are located in North America (45%) and the EU (35%).
2. Currently, more than 60% of cell line development service providers focus on the development and generation of mammalian cell lines, which are the most popular due to their ability to produce highly complex recombinant proteins, antibodies and vaccines that cannot be produced in other types of cell lines. Microbial cell lines are the second most important type; approximately 15% of the companies that we identified claim to provide microbial cell line development services.
3. Cell lines are used for several purposes such as R&D studies, biomanufacturing, diagnostics and tissue engineering. Majority of the companies (over 45%) produce cell lines for R&D purposes; this is followed by companies producing cell lines for biomanufacturing purposes (over 40%). R&D activities include the production of cell based assays, reporter cell lines, ion channel expressing cell lines, drug discovery and screening, and production of non-GMP grade antibodies and other proteins. Examples of companies providing cell lines for R&D applications include (in alphabetical order) Abcam, Altogen Labs, Applied Biological Materials, ATGCell, Bhat Bio-Tech, BPS Bioscience, CreaCell, DiscoverX, Eurofins Scientific, Euroscreen, GeneCopoeia GVK Biosciences, InvivoGen, SB Drug Discovery, System Biosciences, Trend Pharma & Tech, Vectalys, WatsonBio Sciences. Similarly, biomanufacturing involves the production of different types of therapeutic products (monoclonal and polyclonal antibodies, recombinant proteins and vaccines) and biosimilars. Examples of companies producing cell lines for biomanufacturing applications include (in alphabetical order) AbbVie, Abzena, Batavia Biosciences, Biovian, Boehringer Ingelheim BioXcellence, CMC Biologics, Cobra Biologics, FUJIFILM Diosynth Biotechnologies, Inno Biologics, LFB Biomanufacturing, MassBiologics and Patheon.
4. More than 20% of the database companies providing cell line development services also offer cell banking (stand-alone service) and approximately 15% provide cell line characterization services (stand-alone service) to their customers. Some other services included as a part of service portfolio are cGMP manufacturing of biologics, fill / finish and services related to reagents / equipments. Examples of companies offering some of the aforementioned services include (in alphabetical order) Celonic, EuBiologics, Fusion Antibodies, Goodwin Biotechnology, Lonza, Nanotherapeutics, ProBioGen, Rentschler Biotechnologie, Selexis and Syngene International.
5. The heightened competition and growing demand for cell lines has resulted in the emergence of several novel and innovative technologies, lowering of manufacturing costs and production timelines. Examples of some companies that have developed proprietary technologies for production of cell lines include (in alphabetical order) Abzena (Composite CHO™ technology), ACROBiosystems (HEKMax® Stable Cell Line Technology), BioFactura (StableFast™ Biomanufacturing Platform), Batavia Biosciences (STEP® technology), Celltheon (SMART™ expression platform), Celonic (CHOvolution™ / SEFEX platform), Cevec Pharmaceuticals (CAP®GO platform) and Selexis (SUREtechnology Platform™).
6. Stakeholders have extensively collaborated during the last few years for a variety of purposes, such as out / in licensing of technologies, development of cell lines for specific drug candidates and acquisition / development of manufacturing facilities. For instance, Progenics Pharmaceuticals (June 2016), Sanofi Biologics (February 2017) and Xencor (November 2016) collaborated with Selexis to gain access to Selexis’ CHO-M Cell Line™ technology and the SUREtechnology Platform. More recently, in February 2017, Lonza and Sanofi entered into a joint venture agreement to establish a large scale mammalian cell culture facility in Visp, Switzerland, for the production of monoclonal antibodies. Earlier, in September 2015, Abzena acquired PacificGMP with an aim to expand its cell line development services. PacificGMP was a provider of contract process development, and non-GMP and cGMP manufacturing services for biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and gene and cell therapy products.
7. We expect the cell line development services market to grow at an annualized rate of ~10% over the course of next decade; this growth will be driven by the robust pipeline of biologics, increasing number of approvals of biological drug candidates, growing adoption of biosimilars, introduction of advanced production technologies, capability and capacity expansions, and the establishment of new cell line generation facilities. As the market evolves, cell lines obtained from mammalian sources will continue to form a major portion of the overall cell line development services market (~80%). North America and EU, with ~40% and ~35% of the current market, respectively, are likely to remain the major manufacturing hubs in the coming decade.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market may evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
 Annual reports
 Investor presentations
 SEC filings
 Industry databases
 News releases from company websites
 Government policy documents
 Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of the cell line development services market over the coming decade.

Chapter 3 provides a general introduction to the various types of cell lines. It includes a detailed discussion on the sources, selection and maintenance conditions, key features, applications and limitations of currently available cell lines. The chapter also provides a brief description of cell line characterization and cell banking services.

Chapter 4 identifies the contract service providers that are actively involved in the development of cell lines. The chapter provides details on the cell line development capabilities of these organizations, geographic location of their facilities, information on the proprietary technology (if any) used by the company for cell line development, type of cell lines produced by the company (recombinant, hybridoma and primary) and applications of the cell lines (such as for R&D activities, biomanufacturing, diagnostics and tissue engineering). The chapter also provides the distribution of companies based on the other services that they offer; these include cell line characterization, cell bank characterization, cell banking, process development, cGMP manufacturing of biologics, fill / finish and commercialization of reagents / equipment.

Chapter 5 presents a detailed analysis of the cell line development services market landscape. It features a schematic representation on world map, highlighting the key geographical locations of cell line manufacturing facilities. Further, we have provided a heat map analysis representing the distribution of companies on the basis of their location, year of establishment and cell line development capabilities. The chapter also provides a logo landscape of companies based on their size (employee base) and source of cell lines produced.

Chapter 6 offers detailed profiles of contract cell line development service providers that have developed proprietary technology / technologies for the production of cell lines. Each profile provides an overview of the company, its financial performance, details on its proprietary technology / technologies, information on its cell line manufacturing capabilities, recent investments / expansions, relevant collaborations and partnerships that have been inked over the last few years, and a comprehensive future outlook.

Chapter 7 features profiles of additional players that offer cell line characterization, cell banking and cGMP production services, apart from cell line development services. However, the companies included in this chapter have not developed any proprietary technology / technologies for producing cell lines.

Chapter 8 features profiles of key non-industry players (cell line repositories) that are playing an active role in providing cell line development services. Each profile provides a brief overview of the organization and the services it offers.

Chapter 9 presents a 10-year sales forecast, highlighting the likely growth of the market for cell lines development services. We have segregated the broader opportunity by source of cell lines (mammalian, microbial, insect-derived and others), regions (North America, Europe, Asia and the Rest of the World) and grade of cell lines (GMP and non-GMP). Our predictions are backed by robust analysis of data procured from both secondary and primary sources. Due to the uncertain nature of the market, we have presented three different growth tracks outlined as the conservative, base and optimistic forecast scenarios.

Chapter 10 presents insights from a survey that we conducted for this study. The participants, who were primarily members of the Senior Management or CXO level representatives, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 11 summarizes the entire report. The chapter presents a list of key takeaways and offers our independent opinion on the current market scenario and trends that are likely to determine the future evolution of this segment of the industry.

Chapter 12 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. In this chapter, we have presented detailed transcripts of discussions held with Fan Chen (VP BioProcessing, LakePharma), Michael Pointek (Managing Director, Artes Biotechnology), Nienke Smits (Business Development, ModiQuest) and Oscar Hoogteijling (Business Development Manager, Bioceros).

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 14 is an appendix, which contains the list of companies and organizations that have been mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies and organizations have been mentioned in the report.
1 Abbott Nutrition
2 AbbVie
3 Abcam
4 ABclonal
5 Abeomics
6 Abgenex
7 ABLogiX
8 Abnova
9 Abzena
10 Acambis
11 Accurus Biosciences
12 ACROBiosystems
13 ACYTE Biotech
14 AdAlta
15 ADIENNE Pharma & Biotech
16 Agenus
17 Agilux Laboratories
18 Alexion
19 Algeta
20 Allele Biotechnology and Pharmaceuticals
21 Alligator Bioscience
22 Altogen Labs
23 America Pharma Source
24 American Type Culture Collection (ATCC)
25 Amgen
26 AMPO Biotechnology
27 AMS Biotechnology (AMSBIO)
28 Analytical Biological Services
29 Antitope
30 Applied Biological Materials
31 Aragen Bioscience
32 Areta International
33 arGEN-X
34 Aristi Biotech
35 ARTES Biotechnology
36 Asahi Glass Company (AGC)
37 AscentGene
38 ASLAN Pharmaceuticals
39 ATGCell
40 ATUM
41 AutekBio
42 Avid Bioservices
43 Babraham Research Campus
44 Batavia Biosciences
45 Baxter
46 Baylor Institute for Immunology Research (BIIR)
47 Bex
48 Bhat Bio-Tech
49 Bilthoven Biologicals
50 Bio Farma Indonesia
51 BioAzure Technologies
52 Bioceros (member of Polpharma Biologics)
53 Biocon
54 BioFactura
55 Bioingenium
56 BioInvenu
57 BioLab Innovative Research Technologies (BLIRT)
58 Biomet
59 Bionova Scientific
60 BioPharmaceuticals Australia
61 Biosettia
62 Biotie Therapies
63 Biovian
64 BioWa
65 Blue Stream Laboratories
66 Boehringer Ingelheim BioXcellence
67 Boston Mountain Biotech
68 BPS Bioscience
69 Bristol-Myers Squibb
70 C&M Biolabs
71 California Department of Public Health Food and Drug
72 California Institute for Regenerative Medicine
73 Capital Biosciences
74 Cell Essentials
75 CellaGenics
76 CellBank Australia
77 Cellomics Technology
78 Cellon
79 Celltheon
80 Cellutron
81 Celonic
82 Celplor
83 Celther Polska
84 Cerbios-Pharma
85 Ceva Santé Animale (Ceva)
86 Cevec Pharmaceuticals
87 Charles River Laboratories
88 CLS Cell Lines Service
89 CMC Biologics
90 Cobra Biologics
91 Columbia University
92 Commissariat général à l’égalité des territoires (CGET)
93 Complix
94 Cook Pharmica
95 Coriell Institute for Medical Research
96 Corning
97 CreaCell
98 Creative Biogene
99 Creative Biolabs
100 Creative BioMart
101 Crown Bioscience
102 Crucell (Johnson & Johnson)
103 Curaxys
104 Cytovance Biologics
105 Dainippon Sumito Pharma
106 DC3 Therapeutics
107 Delphi Genetics
108 DiscoverX
109 Dundee Cell Products
110 Eden Biodesign
111 EirGenix
112 Elabscience Biotechnology
113 EMD Serono
114 Emergent BioSolutions
115 EMP Genetech
116 EpiGex
117 Eton Bioscience
118 EuBiologics
119 Eugenom
120 Eurofins Scientific Scientific
121 European Collection of Authenticated Cell Cultures (ECACC)
122 European Equity Partners
123 Euroscreen
124 Evercyte
125 Evotec
126 ExcellGene
127 ExonBIO
128 ExpreS2ion Biotechnologies
129 FairJourney Biologics (FJB)
130 Faron Pharmaceuticals
131 Finnish Bioindustries (FIB)
132 Finnish Fair Foundation
133 FivePrime Therapeutics
134 France Research North & South AIDS-HIV Hepatitis ANRS (National Health Agency for Research on AIDS and Hepatitis)
135 FUJIFILM Diosynth Biotechnologies
136 Fusion Antibodies
137 G&P Biosciences
138 Gala Biotech
139 GamaMabs Pharma
140 GATC Biotech
141 GE Capital
142 GE Equity International Mauritius
143 Gemini Biosciences
144 GeneBeyond
145 GeneCopoeia
146 GENENMED
147 Genlantis
148 GenScript
149 GlaxoSmithKline
150 Goodwin Biotechnology
151 GTP Technology
152 GVK Biosciences (GVK BIO)
153 Harvest Moon Pharmaceuticals
154 HealthTech and Medicines Knowledge Transfer Network
155 Heidelberg Pharma
156 Hera BioLabs
157 Horizon Discovery Group
158 Hyprocell
159 ibidi
160 IBI-Lorenzini
161 ICOS Corporation
162 ImmuNext
163 Immunostep
164 Inno Bio Ventures
165 Inno Biologics
166 Innoprot
167 Innoven Partenaires
168 InSCREENeX
169 Institut national de la santé et de la recherche médicale INSERM (National Institute of Health and Medical Research)
170 Institute of Biotechnology (Research Center Juelich)
171 InVivo BioTech Services (part of BRUKER Daltonics)
172 InvivoGen
173 Irvine Scientific
174 Jenner Institute, Oxford University
175 JHL Biotech
176 JRS Pharma
177 JSR Life Sciences
178 KAHR Medical
179 KBI Biopharma
180 Kodiak Sciences
181 Korea-Seoul Life Science Fund (KSLSF)
182 LakePharma
183 Leibniz-Institut DSMZ - Deutsche Sammlung von Mikroorganismen und Zellkulturen
184 LFB Biomanufacturing
185 LFB Biotechnologies
186 Lonza
187 LPB Group
188 Lubris BioPharma
189 Mabion
190 MabPlex
191 Malaysian National Pharmaceutical Control Bureau (NPCB)
192 MassBiologics
193 MedImmune
194 Merck
195 Merica Technologies
196 Merus
197 MGC Pharmaceuticals
198 Minapharm Pharmaceuticals
199 ModiQuest
200 Monitor Clipper Partners
201 Multispan
202 Nanotherapeutics
203 National Biologics Facility
204 National Human Genome Research Institute
205 National Institute of Aging
206 National Institutes of Health (NIH)
207 New England Biolabs
208 Noble Life Sciences
209 NorClone Biotech Laboratories
210 Novartis
211 Novatein Biosciences
212 Novoprotein
213 Nunc
214 Oak BioSciences
215 Octoplus
216 OncoMed Pharmaceuticals
217 OncoSynergy
218 OneWorld Biotech
219 OSE Immnunotherapeutics
220 Oxford Expression Technologies
221 Oxford Genetics
222 Oxford Immunotec
223 Oxford Leadership
224 PacificGMP
225 Paragon Bioservices
226 PATH
227 Patheon
228 PBM Capital Group
229 Pfizer
230 Pharmaron
231 Pieris Pharmaceuticals
232 Polymun Scientific
233 PolyTherics
234 Precision Antibody
235 Premas Biotech
236 ProBioGen
237 Procter & Gamble
238 Profacgen
239 Progenics Pharmaceuticals
240 Promosome
241 ProNovus Biosciences
242 Protein Sciences
243 Protein Technologies
244 ProteoCell
245 PX'Therapeutics
246 RD-Biotech
247 Recopharma
248 Rentschler Biotechnologie
249 RIKEN BioResource Center
250 Roche
251 Rockland Immunochemicals
252 Rodon Biologics
253 RuiYi
254 SAL Scientific
255 Sanofi Biologics
256 Sanofi Pasteur
257 Sartorius Stedim Biotech (SSB)
258 Sartorius Stedim Cellca
259 SB Drug Discovery
260 SB Protein Expression
261 Selexis
262 Senior Housing Properties Trust
263 Serum Institute of India
264 Shanghai Genomics
265 Shanghai Henlius Biotech
266 Shanghai Medicilon
267 Sheffield University
268 Sigma Aldrich
269 Signosis
270 SinoBiological
271 Slovay Pharmaceuticals
272 Sorrento Therapeutics
273 Speed BioSystems
274 STC Biologics
275 Sundia MediTech
276 Sunomix Biosciences
277 Swedish Orphan Biovitrium
278 Syd Labs
279 Symphogen
280 Syngene International
281 System Biosciences
282 TaiMed Biologics
283 Tanvex BioPharma
284 TCG Lifesciences
285 TeneoBio
286 Terumo
287 Teva Pharmachemie
288 Texcell
289 TG Therapeutics
290 The Antibody Lab
291 The Chemistry Research Soluton (TCRS)
292 The Global Health Investment Fund I (GHIF)
293 The Helmholtz Protein Sample Production Facility (PSPF)
294 Therapure Biopharma
295 Thermo Fisher Scientific
296 Tizona Therapeutics
297 TPG Biologics
298 TransViragen
299 Trend Pharma & Tech
300 Trenzyme
301 Triangle Research Labs (TRL)
302 TwinHelix
303 UCL Institute of Ophthalmology
304 UGA Biopharma
305 United BioLabs
306 University College London (UCL)
307 University of Franche Comté
308 University of Oxford
309 UvA Holding
310 Valneva Austria
311 Vectalys
312 VxP Biologics
313 Warwick Effect Polymers
314 WatsonBio Sciences
315 White Oak Global Advisors
316 WIL Research
317 Wockhardt
318 WuXi AppTec
319 WuXi Biologics
320 WuXi PharmaTec
321 Xencor
322 XOMA Corporation
323 Zymeworks


1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. Executive Summary
3. Introduction
3.1. Chapter Overview
3.2. Introduction to Cell Culture
3.2.1. Primary Cell Culture
3.2.2. Secondary Cell Culture
3.3. Types of Cell Lines
3.3.1. Recombinant Cell Lines
3.3.2. Hybridoma Cell Lines
3.3.3. Finite Cell Lines
3.3.4. Continuous Cell Lines
3.4. Sources of Cell Lines
3.4.1. Mammalian
3.4.2. Non-Mammalian
3.5. Selection of a Cell Line
3.6. Maintenance of Cell Lines
3.7. Key Features of a Cell Lines
3.8. Applications of Cell Lines
3.9. Key Concerns Associated with Cell Lines
3.10. Cell Line Characterization
3.11. Cell Banking
3.12. Need for Outsourcing Cell Line Related Operations
4. Market Overview
4.1. Chapter Overview
4.2. Cell Line Development Services Providers: Market Landscape
4.2.1. Distribution by Location of Manufacturing Facility
4.2.2. Distribution by Source of Cell Lines
4.2.3. Distribution by Type and Applications of Cell Lines
4.2.4. Distribution by Other Services Related to Cell Line Development
5. Competitive Landscape
5.1. Chapter Overview
5.2. Regional Analysis
5.3. Heat Map Analysis
5.4. Analysis by Source of Cell Lines and Size of Company
6. Company Profiles of Key Players
6.1. Chapter Overview
6.2. Abzena
6.2.1. Company Overview
6.2.2. Financial Performance
6.2.3. Cell Line Development Services and Technology Platforms
6.2.4. Manufacturing Facilities
6.2.5. Recent Developments
6.2.5.1. Collaborations
6.2.5.2. Investments and Expansions
6.2.5.3. Acquisitions
6.2.6. Future Outlook
6.3. Batavia Biosciences
6.3.1. Company Overview
6.3.2. Cell Line Development Services and Technology Platforms
6.3.3. Manufacturing Facilities
6.3.4. Recent Developments
6.3.4.1. Collaborations
6.3.4.2. Investments and Expansions
6.3.5. Future Outlook
6.4. Celonic
6.4.1. Company Overview
6.4.2. Cell Line Development Services and Technology Platforms
6.4.3. Manufacturing Facilities
6.4.4. Recent Developments
6.4.4.1. Collaborations
6.4.4.2. Investments and Expansions
6.4.5. Future Outlook
6.5. CMC Biologics
6.5.1. Company Overview
6.5.2. Cell Line Development Services and Technology Platforms
6.5.3. Manufacturing Facilities
6.5.4. Recent Developments
6.5.4.1. Collaborations
6.5.4.2. Investments and Expansions
6.5.4.3. Acquisitions
6.5.5. Future Outlook
6.6. Cobra Biologics
6.6.1. Company Overview
6.6.2. Financial Performance
6.6.3. Cell Line Development Services and Technology Platforms
6.6.4. Recent Developments
6.6.4.1. Collaborations
6.6.4.2. Investments and Expansions
6.6.5. Future Outlook
6.7. Hyprocell
6.7.1. Company Overview
6.7.2. Cell Line Development Services and Technology Platforms
6.7.3. Future Outlook
6.8. LFB Biomanufacturing
6.8.1. Company Overview
6.8.2. Financial Performance
6.8.3. Cell Line Development Services and Technology Platforms
6.8.4. Manufacturing Facilities
6.8.5. Recent Developments
6.8.5.1. Collaborations
6.8.5.2. Investments and Expansions
6.8.6. Future Outlook
6.9. Lonza
6.9.1. Company Overview
6.9.2. Financial Performance
6.9.3. Cell Line Development Services and Technology Platforms
6.9.4. Manufacturing Facilities
6.9.5. Recent Developments
6.9.5.1. Collaborations
6.9.5.2. Investments and Expansions
6.9.5.3. Acquisitions
6.9.6. Future Outlook
6.10. ProBioGen
6.10.1. Company Overview
6.10.2. Cell Line Development Services and Technology Platforms
6.10.3. Recent Developments
6.10.3.1. Collaborations
6.10.3.2. Investments and Expansions
6.10.4. Future Outlook
6.11. Selexis
6.11.1. Company Overview
6.11.2. Cell Line Development Services and Technology Platforms
6.11.3. Recent Developments
6.11.3.1. Collaborations
6.11.3.2. Investments and Expansions
6.11.4. Future Oulook
6.12. trenzyme
6.12.1. Company Overview
6.12.2. Cell Line Development Services and Technology Platforms
6.12.3. Recent Developments
6.12.3.1. Collaborations
6.12.4. Future Outlook
7. Company Profiles of Additional Players
7.1. Chapter Overview
7.2. Biovian
7.3. Charles River Laboratories
7.4. EuBiologics
7.5. Inno Biologics
7.6. Nanotherapeutics
7.7. Oxford Genetics
7.8. RD-Biotech
7.9. Syngene International
7.10. TPG Biologics
7.11. WuXi Biologics
8. Cell Line Repositories
8.1. Chapter Overview
8.2. American Type Culture Collection (ATCC)
8.2.1. Overview
8.2.2. Services Portfolio
8.3. Leibniz Institute DSMZ
8.3.1. Overview
8.3.2. Services Portfolio
8.4. European Collection of Authenticated Cell Cultures (ECACC)
8.4.1. Overview
8.4.2. Services Portfolio
8.5. Coriell Institute for Medical Research
8.5.1. Overview
8.5.1.1. Services Portfolio
9. Market Forecast
9.1. Chapter Overview
9.2. Forecast Methodology
9.3. Input Data Tables and Assumptions
9.4. Cell Line Development Services Market Outlook, 2017-2027
9.5. Distribution of Future Opportunity by Source of Cell Lines
9.5.1. Cell Line Development Services Market for Mammalian Cells, 2017-2027
9.5.2. Cell Line Development Services Market for Microbial Cells, 2017-2027
9.5.3. Cell Line Development Services Market for Insect Cells, 2017-2027
9.5.4. Cell Line Development Services Market for Other Cells, 2017-2027
9.6. Distribution of Future Opportunity by Geography
9.6.1. Cell Line Development Services Market in North America, 2017-2027
9.6.2. Cell Line Development Services Market in the EU, 2017-2027
9.6.3. Cell Line Development Services Market in Asia, 2017-2027
9.6.4. Cell Line Development Services Market in the Rest of the World, 2017-2027
9.7. Distribution of Future Opportunity by Grade of Cell Lines
9.7.1. Cell Line Development Services Market for GMP Grade Cell Lines, 2017-2027
9.7.2. Cell Line Development Services Market for Non-GMP Grade Cell Lines, 2017-2027
10. Survey Analysis
10.1. Chapter Overview
10.1.1. Overview of Respondents
10.1.2. Seniority Level of Respondents
10.2. Type of Cell Lines
10.3. Source of Cell Lines
10.4. Applications of Cell Lines
10.5. Cell Line Characterization Services
10.6. Cell Banking Services
10.7. Biologics Manufacturing Services
10.8. Fill / Finish Services
11. Conclusion
11.1. Mammalian and Microbial Cell Lines Continue to be Preferred Over those Derived from Other Sources
11.2. Cell Line Characterization, Cell Banking, Process Development and Other Affiliated Services also form an Important Part of the Services Portfolio of Most of the Players
11.3. Innovative Technologies Developed to Optimize and Scale-up the Overall Cell Line Development Process are Emerging as Key Enablers to Future Growth
11.4. Companies Headquartered in the US and EU Dominate the Market Landscape; Asia is Emerging as an Alternative Destination for Provision of such Services
11.5. The Market Continues to Witness Significant Partnership Activity Indicating a Lucrative Future Potential
11.6. Escalating Biomanufacturing Activities and R&D Initiatives are Expected to Act as Key Drivers of the Market
11.7. Overall, the Cell Line Development Services Market is Poised to Grow at a Steady Pace in the Coming Decade
12. Interview Transcripts
12.1. Chapter Overview
12.2. Fan Chen, Vice President BioProcessing, LakePharma
12.3. Michael Pointek, Managing Director, ARTES Biotechnology
12.4. Nienke Smits, Business Development, ModiQuest
12.5. Oscar Hoogteijling, Business Development Manager, Bioceros
13. Appendix 1: Tabulated Data
14. Appendix 2: List of Companies and Organizations
LIST OF FIGURES
Figure 3.1 Primary and Secondary Cell Culture
Figure 3.2 Recombinant Cell Line Development
Figure 3.3 Hybridoma Cell Line Development
Figure 3.4 Sources of Non-Mammalian Cell Lines
Figure 3.5 Applications of Cell Lines
Figure 3.6 Factors Affecting the Utility of Cell Lines
Figure 4.1 Cell Line Development Services Providers: Distribution by Location of Manufacturing Facility (Regions)
Figure 4.2 Cell Line Development Services Providers: Distribution by Location of Manufacturing Facility (Countries)
Figure 4.3 Cell Line Development Services Providers: Distribution by Source of Cell Lines
Figure 4.4 Cell Line Development Services Providers: Distribution by Type of Cell Lines
Figure 4.5 Cell Line Development Services Providers: Distribution by Applications of Cell Lines
Figure 4.6 Cell Line Development Services Providers: Distribution by Other Related Services
Figure 5.1 Regional Analysis: Distribution by Location of Manufacturing Facility
Figure 5.2 Heat Map Analysis: Distribution by Location of Manufacturing Facility and Year of Establishment
Figure 5.3 Cell Line Development Services Providers (North America): Distribution by Source of Cell Lines and Size of Company
Figure 5.4 Cell Line Development Services Providers (EU): Distribution by Source of Cell Lines and Size of Company
Figure 5.5 Cell Line Development Services Providers (Asia): Distribution by Source of Cell Lines and Size of Company
Figure 6.1 Abzena: Revenues, FY 2014-FY H1 2017 (EUR Million)
Figure 6.2 Abzena: Revenues by Business Divisions, FY 2015-FY 2016 (EUR Million)
Figure 6.3 Celonic: CHOvolution Technology
Figure 6.4 LFB Group: Revenues, FY 2012-FY 2016 (EUR Million)
Figure 6.5 LFB Group: Revenues by Therapeutic Areas and Services, 2016 (EUR Million)
Figure 6.6 LFB Biomanufacturing: Cell Line Development Process
Figure 6.7 Lonza: Custom Contract Manufacturing Services
Figure 6.8 Lonza: Revenues, FY 2012-FY 2016 (CHF Million)
Figure 6.9 GS Gene Expression System: Working Principle
Figure 6.10 Selexis: Cell Line Development Process
Figure 6.11 trenzyme: Cell Line Development Process
Figure 8.1 ATCC: Services Portfolio
Figure 8.2 Leibniz Institute DSMZ: Biological Material Collection
Figure 8.3 ECACC: Biological Material Collection
Figure 8.4 ECACC: Services Portfolio
Figure 8.5 Coriell Institute of Medical Research: Operating Segments
Figure 8.6 Coriell Institute for Medical Research: Services Portfolio
Figure 9.1 Cell Line Development Services Market, 2017-2027 (USD Billion)
Figure 9.2 Cell Line Development Services Market, 2017 and 2027: Distribution by Source of Cell Lines (USD Million)
Figure 9.3 Cell Line Development Services Market for Mammalian Cells, 2017-2027 (USD Billion)
Figure 9.4 Cell Line Development Services Market for Microbial Cells, 2017-2027 (USD Million)
Figure 9.5 Cell Line Development Services Market for Insect Cells, 2017-2027 (USD Million)
Figure 9.6 Cell Line Development Services Market for Other Cells, 2017-2027 (USD Million)
Figure 9.7 Cell Line Development Services Market, 2017 and 2027: Distribution by Regions (USD Million)
Figure 9.8 Cell Line Development Services Market in North America, 2017-2027 (USD Million)
Figure 9.9 Cell Line Development Services Market in the EU, 2017-2027 (USD Million)
Figure 9.10 Cell Line Development Services Market in Asia, 2017-2027 (USD Million)
Figure 9.11 Cell Line Development Services Market in the Rest of the World, 2017-2027 (USD Million)
Figure 9.12 Cell Line Development Services Market, 2017 and 2027: Distribution by Grade of Cell Lines (USD Million)
Figure 9.13 Cell Line Development Services Market for GMP Grade Cell Lines, 2017-2027 (USD Billion)
Figure 9.14 Cell Line Development Services Market for Non-GMP Grade Cell Lines, 2017-2027 (USD Million)
Figure 10.1 Survey Analysis: Distribution by Location of Organization
Figure 10.2 Survey Analysis: Distribution by Location of Manufacturing Facilities
Figure 10.3 Survey Analysis: Distribution by Seniority Level of Respondents
Figure 10.4 Survey Analysis: Distribution by Types of Cell Lines
Figure 10.5 Survey Analysis: Distribution by Source of Cell Lines
Figure 10.6 Survey Analysis: Distribution by Applications of Cell Lines
Figure 10.7 Survey Analysis: Cell Line Characterization Services
Figure 10.8 Survey Analysis: Cell Banking Services
Figure 10.9 Survey Analysis: Biologics Manufacturing Services
Figure 10.10 Survey Analysis: Fill / Finish Services
Figure 11.1 Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Source of Cell Lines
Figure 11.2 Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Regions
Figure 11.3 Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Grade of Cell Lines
LIST OF TABLES
Table 3.1 Comparison of Properties of Finite and Continuous Cell line
Table 3.2 Human Cell Lines and Therapeutic Protein Products
Table 3.3 Cell Lines and Viral Vaccine Products
Table 4.1 Cell Line Development Services Providers: List of Companies
Table 4.2 Cell Line Development Services Providers: Distribution by Source of Cell Lines
Table 4.3 Cell Line Development Services Providers: Distribution by Type and Application of Cell Lines
Table 4.4 Cell Line Development Services Providers: Distribution by Other Related Services
Table 6.1 CMC Biologics: Mammalian and Microbial cGMP Manufacturing Capabilities
Table 9.1 Input Data and Assumptions: Distribution of Cell Line Development Services Providers by Size of the Company and Grade of Cell Lines
Table 9.2 Input Data and Assumptions: Distribution of Price of Cell Lines by Source and Grade of Cell Lines
Table 9.3 Input Data and Assumptions: Distribution of Number of Projects Undertaken by Size of Company
Table 9.4 Input Data and Assumptions: Distribution of Source of Cell Lines by Percentage of Biopharmaceuticals Produced
Table 10.1 Survey Responses: Overview of the Respondents
Table 10.2 Survey Responses: Seniority Level of Respondents
Table 10.3 Survey Responses: Types of Cell Lines
Table 10.4 Survey Responses: Source of Cell Lines
Table 10.5 Survey Responses: Applications of Cell Lines
Table 10.6 Survey Responses: Cell Line Characterization Services
Table 10.7 Survey Responses: Cell Banking Services
Table 10.8 Survey Responses: Biologics Manufacturing Services
Table 10.9 Survey Responses: Fill / Finish Services
Table 13.1 Cell Line Development Services Providers: Distribution by Location of Manufacturing Facility (Regions)
Table 13.2 Cell Line Development Services Providers: Distribution by Location of Manufacturing Facility (Countries)
Table 13.3 Cell Line Development Services Providers: Distribution by Source of Cell Lines
Table 13.4 Cell Line Development Services Providers: Distribution by Type of Cell Lines
Table 13.5 Cell Line Development Services Providers: Distribution by Applications of Cell Lines
Table 13.6 Cell Line Development Services Providers: Distribution by Other Related Services
Table 13.7 Abzena: Revenues, FY 2014-FY H1 2017 (EUR Million)
Table 13.8 Abzena: Revenues by Business Divisions, FY 2015-2016 (EUR Million)
Table 13.9 LFB Group: Revenues, FY 2012-FY 2016 (EUR Million)
Table 13.10 LFB Group: Revenues by Therapeutic Areas and Services, 2016 (EUR Million)
Table 13.11 Lonza: Revenues, FY 2012-FY 2016 (CHF Million)
Table 13.12 Cell Line Development Services Market, 2017-2027: Base Scenario (USD Billion)
Table 13.13 Cell Line Development Services Market, 2017-2027: Conservative Scenario (USD Billion)
Table 13.14 Cell Line Development Services Market, 2017-2027: Optimistic Scenario (USD Billion)
Table 13.15 Cell Line Development Services Market, 2017 and 2027: Distribution by Source of Cell Lines (USD Million)
Table 13.16 Cell Line Development Services Market for Mammalian Cells, 2017-2027: Base Scenario (USD Billion)
Table 13.17 Cell Line Development Services Market for Mammalian Cells, 2017-2027: Conservative Scenario (USD Billion)
Table 13.18 Cell Line Development Services Market for Mammalian Cells, 2017-2027: Optimistic Scenario (USD Billion)
Table 13.19 Cell Line Development Services Market for Microbial Cells, 2017-2027: Base Scenario (USD Million)
Table 13.20 Cell Line Development Services Market for Microbial Cells, 2017-2027: Conservative Scenario (USD Million)
Table 13.21 Cell Line Development Services Market for Microbial Cells, 2017-2027: Optimistic Scenario (USD Million)
Table 13.22 Cell Line Development Services Market for Insect Cells, 2017-2027: Base Scenario (USD Million)
Table 13.23 Cell Line Development Services Market for Insect Cells, 2017-2027: Conservative Scenario (USD Million)
Table 13.24 Cell Line Development Services Market for Insect Cells, 2017-2027: Optimistic Scenario (USD Million)
Table 13.25 Cell Line Development Services Market for Other Cells, 2017-2027: Base Scenario (USD Million)
Table 13.26 Cell Line Development Services Market for Other Cells, 2017-2027: Conservative Scenario (USD Million)
Table 13.27 Cell Line Development Services Market for Other Cells, 2017-2027: Optimistic Scenario (USD Million)
Table 13.28 Cell Line Development Services Market, 2017 and 2027: Distribution by Regions (USD Million)
Table 13.29 Cell Line Development Services Market in North America, 2017-2027: Base Scenario (USD Million)
Table 13.30 Cell Line Development Services Market in North America, 2017-2027: Conservative Scenario (USD Million)
Table 13.31 Cell Line Development Services Market in North America, 2017-2027: Optimistic Scenario (USD Million)
Table 13.32 Cell Line Development Services Market in the EU, 2017-2027: Base Scenario (USD Million)
Table 13.33 Cell Line Development Services Market in the EU, 2017-2027: Conservative Scenario (USD Million)
Table 13.34 Cell Line Development Services Market in the EU, 2017-2027: Optimistic Scenario (USD Million)
Table 13.35 Cell Line Development Services Market in Asia, 2017-2027: Base Scenario (USD Million)
Table 13.36 Cell Line Development Services Market in Asia, 2017-2027: Conservative Scenario (USD Million)
Table 13.37 Cell Line Development Services Market in Asia, 2017-2027: Optimistic Scenario (USD Million)
Table 13.38 Cell Line Development Services Market in the Rest of the World, 2017-2027: Base Scenario (USD Million)
Table 13.39 Cell Line Development Services Market in the Rest of the World, 2017-2027: Conservative Scenario (USD Million)
Table 13.40 Cell Line Development Services Market in the Rest of the World, 2017-2027: Optimistic Scenario (USD Million)
Table 13.41 Cell Line Development Services Market, 2017 and 2027: Distribution by Grade of Cell Lines (USD Million)
Table 13.42 Cell Line Development Services Market for GMP Grade Cell Lines, 2017-2027: Base Scenario (USD Billion)
Table 13.43 Cell Line Development Services Market for GMP Grade Cell Lines, 2017-2027: Conservative Scenario (USD Billion)
Table 13.44 Cell Line Development Services Market for GMP Grade Cell Lines, 2017-2027: Optimistic Scenario (USD Billion)
Table 13.45 Cell Line Development Services Market for Non-GMP Cell Lines, 2017-2027: Base Scenario (USD Million)
Table 13.46 Cell Line Development Services Market for Non-GMP Grade Cell Lines, 2017-2027: Conservative Scenario (USD Million)
Table 13.47 Cell Line Development Services Market for Non-GMP Grade Cell Lines, 2017-2027: Optimistic Scenario (USD Million)
Table 13.48 Survey Analysis: Distribution by Location of Organization
Table 13.49 Survey Analysis: Distribution by Location of Manufacturing Facilities
Table 13.50 Survey Analysis: Distribution by Seniority Level of Respondents
Table 13.51 Survey Analysis: Distribution by Type of Cell Lines
Table 13.52 Survey Analysis: Distribution by Source of Cell Lines
Table 13.53 Survey Analysis: Distribution by Applications of Cell Lines
Table 13.54 Survey Analysis: Cell Line Characterization Services
Table 13.55 Survey Analysis: Cell Banking Services
Table 13.56 Survey Analysis: Biologics Manufacturing Services
Table 13.57 Survey Analysis: Fill / Finish Services
Table 13.58 Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Source of Cell Lines
Table 13.59 Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Regions
Table 13.60 Cell Line Development Services Market, 2017-2027 (USD Million): Distribution by Grade of Cell Lines

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report